Risk factors of survival after liver transplantation for HCC: A multivariate single-center analysis

Clinical Transplantation

Volumn 25, Issue 5, 2011, Pages

  Hoffmann, Katrin ^a   Hinz, Ulf ^a   Hillebrand, Norbert ^a   Radeleff, Boris A ^a   Ganten, Tom M ^a   Schirmacher, Peter ^a   Schmidt, Jan ^a   Büchler, Markus W ^a   Schemmer, Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Selection criteria; Transarterial chemoembolization; Tumor recurrence

Indexed keywords

CARBOPLATIN; IODINATED POPPYSEED OIL;

ADULT; ARTERY THROMBOSIS; ARTICLE; BILIARY TRACT DISEASE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RADIOFREQUENCY ABLATION; RECURRENT CANCER; RETRANSPLANTATION; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80054100941     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01465.x     Document Type: Article

References (47)

1. Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 2009: 50: 89.
2. El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999: 340: 745.
3. Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2003: 362: 1907.
4. Mazzaferro V, Regalia E, Dogia R, Andreola S et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996: 334: 693.
5. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999: 30: 1434.
6. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001: 35: 421.
7. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999: 19: 329.
8. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009: 10: 35.
9. Llovet JM, Mas X, Aponte JJ et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002: 50: 123.
10. Mazzaferro V, Battiston C, Perrone S et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004: 240: 900.
11. Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997: 226: 688.
12. Decaens T, Roudot-Thoraval F, Bresson-Hadni S et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005: 11: 767.
13. Porrett PM, Peterman H, Rosen M et al. Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl 2006: 12: 665.
14. Otto G, Herber S, Heise M et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006: 12: 1260.
15. Millonig G, Graziadei IW, Freund MC et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007: 13: 272.
16. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009: 45: 228.
17. Belghiti J, Panis Y, Sauvanet A, Gayet B, Fekete F. A new technique of side to side caval anastomosis during orthotopic hepatic transplantation without inferior vena caval occlusion. Surg Gynecol Obstet 1992: 175: 270.
18. Lerut J, Gertsch P, Blumgart LH. "Piggy back" adult orthotopic liver transplantation. Helv Chir Acta 1989: 56: 527.
19. Schemmer P, Nickkholgh A, Hinz U et al. Extended donor criteria have no negative impact on early outcome after liver transplantation: a single-center multivariate analysis. Transplant Proc 2007: 39: 529.
20. Nickkholgh A, Weitz J, Encke J et al. Utilization of extended donor criteria in liver transplantation: a comprehensive review of the literature. Nephrol Dial Transplant 2007: 22(Suppl 8): 29.
21. Briceno J, Marchal T, Padillo J. Influence of marginal donors on liver preservation injury. Transplantation 2002: 74: 522.
22. Kniepeiss D, Iberer F, Grasser B. A single-center experience with retrograde reperfusion in liver transplantation. Transpl Int 2003: 16: 730.
23. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003: 9: 557.
24. Maddala YK, Stadheim L, Andrews JC et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 2004: 10: 449.
25. Chapman WC, Majella Doyle MB, Stuart JE et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008: 248: 617.
26. Jonas S, Al-Abadi H, Benckert C et al. Prognostic significance of the DNA-index in liver transplantation for hepatocellular carcinoma in cirrhosis. Ann Surg 2009: 250: 1008.
27. Obed A, Tsui TY, Schnitzbauer AA et al. Liver transplantation as curative approach for advanced hepatocellular carcinoma: is it justified? Langenbecks Arch Surg 2008: 393: 141.
28. Sotiropoulus GC, Malago M, Bockhorn M et al. Liver transplantation for hepatocellular carcinoma and cirrhosis in candidates with undetectable or very low alpha-fetoprotein levels: is an expansion of teh listing criteria justified. Hepatogastroenterology 2008: 55: 1671.
29. Verna EC, De Martin E, Burra P et al. The impact of hepatitis C and biliary complications on patient and graft survival following liver transplantation. Am J Transplant 2009: 9: 1398.
30. Aguiliera V, Berenguer M, Rubin A et al. Cirrhosis of mixed etiology (hepatitis c virus and alcohol): posttransplantation outcome-comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis. Liver Transpl 2009: 15: 79.
31. Mangus RS, Fridell JA, Vianna RM, Cooper AB, Jones DT, Tector AJ. Use of the piggyback hepatectomy technique in liver transplant recipients with hepatocellular carcinoma. Transplantation 2008: 10: 1496.
32. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001: 33: 1394.
33. Yao FY, Xiao L, Bass NM, Kerlan AK, Ascher NL, Roberts BJ. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007: 7: 2587.
34. Duffy JP, Vardanian A, Benjamin E et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007: 246: 502.
35. Majno P, Mazzaferro V. Living donor liver transplantation for hepatocellular carcinoma exceeding conventional criteria: questions, answers and demands for a common language. Liver Transpl 2006: 12: 896.
36. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003: 37: 429.
37. Vitale A, Boccagni P, Brolese A et al. Progression of hepatocellular carcinoma before liver transplantation: dropout or liver transplantation? Transplant Proc 2009: 41: 1264.
38. Yao FY, Bass NM, Nikolai B et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002: 8: 873.
39. Suzuki H, Mori M, Kawaguchi C, Adachi M, Miura S, Ishii H. Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma. Int J Oncol 1999: 14: 1087.
40. Shim JH, Park JW, Kim JH et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008: 99: 2037.
41. Poon RT, Lau C, Yu WC, Fan ST, Wong J. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep 2004: 11: 1077.
42. ® versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 2008: 8: 349.
43. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004: 5(Suppl 1): S179.
44. Obed A, Beham A, Pullmann K, Becker H, Schlitt HJ, Lorf T. Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation. World J Gastroenterol 2007: 5: 761.
45. Chau GY, Lee AF, Tsay SH et al. Clinicopathological significance of survivin expression in patients with hepatocellular carcinoma. Histopathology 2007: 51: 204.
46. Yamamoto Y, Kosaka N, Tanaka M et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 2009: 14: 529.
47. Shirakawa H, Suzuki H, Shimomura M et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009: 100: 1403.